News Details

NEW ORLEANS – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today introduced two new biodiesel platforms at PITTCON^® 2008, Booth #2555. The PerkinElmer EcoAnalytix^™ Biodiesel Application Platforms are designed to help biodiesel manufacturers ensure the quality of their fuel and meet regulatory compliance for both ASTM and EN standards. The platforms are part of PerkinElmer's EcoAnalytix^™ initiative, a collaborative problem-solving initiative that creates application-based solutions to improve business ecosystems while supporting local, regional and global initiatives that contribute to a healthier worldwide ecosystem.

“As energy manufacturers around the world explore and commit to using more biodiesel, it is critically important to ensure that the promise of cost-effective, high quality biodiesel can be realized,” said Alessandra Rasmussen, Director of EcoAnalytix^™ and Strategic Programs, PerkinElmer Life and Analytical Sciences. “Our goal is to provide biodiesel development laboratories with all of the necessary tools they need to get up and running quickly and to ensure the quality of their fuel throughout each stage of production. These platforms help manufacturers confirm that their renewable fuels burn clean, meet regulatory requirements and protect expensive engine components from damage.”

The platforms include the EcoAnalytix^™ Glycerin & Methanol Analyzer for the analysis of free and total glycerin and residual alcohol in biodiesel, the EcoAnalytix^™ Trace Metals Biodiesel Analyzer based on the Optima^™ 7000 ICP Optical Emission Spectroscopy (ICP-OES) for testing Group I and Group II metals and phosphorus, and EcoAnalytix^™ FAME Biodiesel Analyzer (for ASTM only) based on the Spectrum^™ 100 FT-IR System for analyzing the properties of biodiesel fuel that are determined by structure of its fatty acid methyl esters.

The EcoAnalytix^™ Glycerin & Methanol Analyzer for the analysis of free and total glycerin and residual alcohol features the Clarus^® 500 Gas Chromatograph (GC) with an innovative dual oven design for the analysis of both free and total glycerin and residual alcohol. The oven design allows laboratories to complete both GC analyses on a single instrument without the need to modify hardware setup; previously two GC instruments or modifications to hardware setup were necessary. “The dual oven increases the manufacturer's productivity by allowing them to conduct two types of analysis in one instrument,” Rasmussen said.

The platforms also include PerkinElmer's LABWORKS^™ Green, a pre-configured software application specifically for the biodiesel industry, application notes, methods standard operating procedures (SOPS) and on-site training.

“Our goal is to provide analysis tools that are easy to use and ensure high quality results, regardless of whether or not the user has a scientific background,” Rasmussen said. “Our analyzer approach provides step-by-step instructions and training to ensure fast ramp-up. This approach ensures higher accuracy and faster time-to-market.”

For more information on PerkinElmer's biodiesel platforms, visit www.perkinelmer.com/biofuels.

About EcoAnalytix^™

The EcoAnalytix^™ initiative is a collaborative problem-solving approach that creates application-based solutions that contribute to a healthier ecosystem worldwide. EcoAnalytix^™ is initially focusing on providing products and support to laboratories conducting environmental, biofuels and food safety analyses. Through partnerships and collaborations that support local, regional and global initiatives, this business leverages PerkinElmer's core technologies, application capabilities, global reach, and thought leadership to improve business ecosystems.

For more information on the PerkinElmer EcoAnalytix^™ initiative, visit http://www.perkinelmer.com/ecoanalytix.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

“PITTCON” is a registered trademark of its owner.

For further information regarding PerkinElmer, please contact:

Media Contact:
Ellen Wein
Euro RSCG Worldwide PR
(412) 456-0986
or
Lesley Sillaman
Euro RSCG Worldwide PR
(412) 456-7839